{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:32:49Z","timestamp":1772134369877,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T00:00:00Z","timestamp":1372982400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"DOI":"10.1038\/emm.2013.58","type":"journal-article","created":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T02:56:08Z","timestamp":1372992968000},"page":"e30-e30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats"],"prefix":"10.1038","volume":"45","author":[{"given":"Tae Jung","family":"Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Yon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyeong Hoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyong Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Min","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,5]]},"reference":[{"key":"BFemm201358_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2337\/diacare.15.3.318","volume":"15","author":"RA DeFronzo","year":"1992","unstructured":"DeFronzo RA, Bonadonna RC, Ferrannini E . Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318\u2013368.","journal-title":"Diabetes Care"},{"key":"BFemm201358_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1210\/edrv.20.6.0385","volume":"20","author":"TJ Kieffer","year":"1999","unstructured":"Kieffer TJ, Habener JF . The glucagon-like peptides. Endocr Rev 1999; 20: 876\u2013913.","journal-title":"Endocr Rev"},{"key":"BFemm201358_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1210\/jcem-63-2-492","volume":"63","author":"MA Nauck","year":"1986","unstructured":"Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492\u2013498.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"BFemm201358_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cen.12167","volume":"80","author":"Tae Jung Oh","year":"2013","unstructured":"Oh TJ, Kim MY, Shin JY, Lee JC, Kim S, Park KS et al. The incretin effect in korean subjects with normal glucose tolerance or type 2 diabetes. Clin Endocrinol (Oxf), (doi:10.1111\/cen.12167).","journal-title":"Clinical Endocrinology"},{"key":"BFemm201358_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/dmr.5610080206","volume":"8","author":"W Creutzfeldt","year":"1992","unstructured":"Creutzfeldt W, Nauck M . Gut hormones and diabetes mellitus. Diabetes Metab Rev 1992; 8: 149\u2013177.","journal-title":"Diabetes Metab Rev"},{"key":"BFemm201358_CR6","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ . Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131\u20132157.","journal-title":"Gastroenterology"},{"key":"BFemm201358_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/B978-0-12-381517-0.00004-7","volume":"84","author":"YM Cho","year":"2010","unstructured":"Cho YM, Kieffer TJ . K-cells and glucose-dependent insulinotropic polypeptide in health and disease. Vitam Horm 2010; 84: 111\u2013150.","journal-title":"Vitam Horm"},{"key":"BFemm201358_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/BF02427280","volume":"29","author":"M Nauck","year":"1986","unstructured":"Nauck M, Stockmann F, Ebert R, Creutzfeldt W . Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46\u201352.","journal-title":"Diabetologia"},{"key":"BFemm201358_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.prevetmed.2011.05.002","volume":"101","author":"H Stege","year":"2011","unstructured":"Stege H, Bagger J, Nielsen JP, Ersboll AK . Effect of breeding strategy and feeding system on the within-herd variation of lean meat percents in Danish slaughter pigs. Prev Vet Med 2011; 101: 73\u201378.","journal-title":"Prev Vet Med"},{"key":"BFemm201358_CR10","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.2337\/db07-0100","volume":"56","author":"FK Knop","year":"2007","unstructured":"Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, Volund A et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007; 56: 1951\u20131959.","journal-title":"Diabetes"},{"key":"BFemm201358_CR11","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.2337\/db06-1033","volume":"56","author":"G Xu","year":"2007","unstructured":"Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007; 56: 1551\u20131558.","journal-title":"Diabetes"},{"key":"BFemm201358_CR12","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.2337\/diabetes.50.5.1004","volume":"50","author":"FC Lynn","year":"2001","unstructured":"Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA . Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001; 50: 1004\u20131011.","journal-title":"Diabetes"},{"key":"BFemm201358_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2337\/db09-1899","volume":"59","author":"JJ Meier","year":"2010","unstructured":"Meier JJ, Nauck MA . Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 2010; 59: 1117\u20131125.","journal-title":"Diabetes"},{"key":"BFemm201358_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00125-010-1986-3","volume":"54","author":"YM Cho","year":"2011","unstructured":"Cho YM, Kieffer TJ . New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 2011; 54: 219\u2013222.","journal-title":"Diabetologia"},{"key":"BFemm201358_CR15","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1210\/jc.2007-2109","volume":"93","author":"CW Chia","year":"2008","unstructured":"Chia CW, Egan JM . Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008; 93: 3703\u20133716.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFemm201358_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"DM Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193\u2013203.","journal-title":"Diabetes Care"},{"key":"BFemm201358_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ . The biology of incretin hormones. Cell Metab 2006; 3: 153\u2013165.","journal-title":"Cell Metab"},{"key":"BFemm201358_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.2337\/diacare.24.4.720","volume":"24","author":"M Zander","year":"2001","unstructured":"Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ . Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 2001; 24: 720\u2013725.","journal-title":"Diabetes Care"},{"key":"BFemm201358_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.metabol.2010.01.001","volume":"60","author":"J Cuthbertson","year":"2011","unstructured":"Cuthbertson J, Patterson S, O'Harte FP, Bell PM . Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism 2011; 60: 52\u201356.","journal-title":"Metabolism"},{"key":"BFemm201358_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2147\/VHRM.S1944","volume":"4","author":"B Ahren","year":"2008","unstructured":"Ahren B . Novel combination treatment of type 2 diabetes DPP-4 inhibition+metformin. Vasc Health Risk Manag 2008; 4: 383\u2013394.","journal-title":"Vasc Health Risk Manag"},{"key":"BFemm201358_CR21","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1056\/NEJM199602293340906","volume":"334","author":"CJ Bailey","year":"1996","unstructured":"Bailey CJ, Turner RC . Metformin. N Engl J Med 1996; 334: 574\u2013579.","journal-title":"N Engl J Med"},{"key":"BFemm201358_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.pharmthera.2012.05.009","volume":"135","author":"YM Cho","year":"2012","unstructured":"Cho YM, Merchant CE, Kieffer TJ . Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Therapeut 2012; 135: 247\u2013278.","journal-title":"Pharmacol Therapeut"},{"key":"BFemm201358_CR23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00125-010-1937-z","volume":"54","author":"A Maida","year":"2011","unstructured":"Maida A, Lamont BJ, Cao X, Drucker DJ . Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia 2011; 54: 339\u2013349.","journal-title":"Diabetologia"},{"key":"BFemm201358_CR24","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.2337\/diabetes.52.9.2331","volume":"52","author":"EH Koh","year":"2003","unstructured":"Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes 2003; 52: 2331\u20132337.","journal-title":"Diabetes"},{"key":"BFemm201358_CR25","doi-asserted-by":"publisher","first-page":"E923","DOI":"10.1152\/ajpendo.00422.2010","volume":"300","author":"M Speck","year":"2011","unstructured":"Speck M, Cho YM, Asadi A, Rubino F, Kieffer TJ . Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. Am J Physiol Endocrinol Metab 2011; 300: E923\u2013E932.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"BFemm201358_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00125-012-2776-x","volume":"56","author":"ZF Kang","year":"2013","unstructured":"Kang ZF, Deng Y, Zhou Y, Fan RR, Chan JC, Laybutt DR et al. Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes. Diabetologia 2013; 56: 423\u2013433.","journal-title":"Diabetologia"},{"key":"BFemm201358_CR27","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2337\/dc08-2335","volume":"32","author":"M Pruski","year":"2009","unstructured":"Pruski M, Krysiak R, Okopien B . Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care 2009; 32: 1421\u20131424.","journal-title":"Diabetes Care"},{"key":"BFemm201358_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1463-1326.2006.00668.x","volume":"9","author":"M Nieuwdorp","year":"2007","unstructured":"Nieuwdorp M, Stroes ES, Kastelein JJ . Normalization of metabolic syndrome using fenofibrate, metformin or their combination. Diabetes Obes Metab 2007; 9: 869\u2013878.","journal-title":"Diabetes Obes Metab"},{"key":"BFemm201358_CR29","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849\u20131861.","journal-title":"Lancet"},{"key":"BFemm201358_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mce.2008.06.013","volume":"297","author":"B Portha","year":"2009","unstructured":"Portha B, Lacraz G, Kergoat M, Homo-Delarche F, Giroix MH, Bailbe D et al. The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes? Mol Cell Endocrinol 2009; 297: 73\u201385.","journal-title":"Mol Cell Endocrinol"},{"key":"BFemm201358_CR31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/BOR.0b013e32832ca447","volume":"21","author":"BL Clarke","year":"2009","unstructured":"Clarke BL, Khosla S . New selective estrogen and androgen receptor modulators. Curr Opin Rheumatol 2009; 21: 374\u2013379.","journal-title":"Curr Opin Rheumatol"},{"key":"BFemm201358_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1172\/JCI10843","volume":"106","author":"JM Olefsky","year":"2000","unstructured":"Olefsky JM . Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000; 106: 467\u2013472.","journal-title":"J Clin Invest"},{"key":"BFemm201358_CR33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/01.ATV.0000154140.73570.00","volume":"25","author":"H Duez","year":"2005","unstructured":"Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G et al. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 2005; 25: 585\u2013591.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Experimental & Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/emm201358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/emm201358","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/emm201358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T15:40:37Z","timestamp":1672933237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/emm201358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,5]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7]]}},"alternative-id":["BFemm201358"],"URL":"https:\/\/doi.org\/10.1038\/emm.2013.58","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718212039.793488791","asserted-by":"object"}]},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,5]]},"assertion":[{"value":"25 March 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}